Organon

OGN · NYSE

$13.76+$0.01 (+0.07%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $13.75

OGN analyst rating

HoldConsensus of 5 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold3
Underperform2
Sell0

12-month price target · 6 analysts

Average $11.48 (−16.6% downside)

Low: $8.08
Now: $13.76
High: $14.70

Upgrades and downgrades

The latest rating actions, newest first

OGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BNP Paribas	Apr 29, 2026	Downgrade	Outperform → Neutral	$12.00 → $14.00	63%
Piper Sandler	Apr 28, 2026	Upgrade	Underweight → Neutral	$5.00 → $14.00	68%
Barclays	Feb 24, 2026	Maintains	Underweight	$7.50 → $8.00	53%
Barclays	Dec 9, 2025	Initiates	Underweight	$7.50	53%
JP Morgan	Nov 11, 2025	Maintains	Underweight	$14.00 → $12.00	65%
Morgan Stanley	Nov 11, 2025	Maintains	Equal-Weight	$10.00 → $9.00	63%

The case for and against

Updated Oct 31, 2025

Bull case

Organon & Co is positioned for positive growth, particularly with its VTAMA product due to anticipated gross-to-net improvements and robust volume increases following recent label expansions in atopic dermatitis. The company's management noted a potentially aggressive sales target of approximately $150 million for 2025, reinforced by access improvements and reduced reliance on coupon support, which could lead to significant quarterly growth in the second half of 2025. Additionally, the company's stable management of selling, general, and administrative expenses further indicates a controlled operational environment supportive of profitability.

Bear case

Organon & Co has faced a significant decline in its stock value, dropping approximately 57% since announcing the acquisition of Dermavant last September, which raises concerns about its financial stability. The company's updated valuation methodology reflects a reduced EV/EBITDA multiple of 7x, down from 8x, indicating increased skepticism regarding future performance amidst a challenging macroeconomic environment. Additionally, despite a slight increase in estimated EBITDA for 2026 to $1,956 million, the lack of visibility into meaningful EBITDA growth further contributes to a negative outlook on the company's stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.